These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36057843)

  • 1. Evaluation of Hemoglobin Response to Treatment With Enarodustat Using Pharmacometric Approach in Japanese Anemic Patients With Chronic Kidney Disease.
    Naruhashi S; Fujii T; Yamada H; Pai SM; Ninomiya N
    J Clin Pharmacol; 2023 Feb; 63(2):180-196. PubMed ID: 36057843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enarodustat Treatment for Renal Anemia in Patients With Non-dialysis Chronic Kidney Disease.
    Mima A
    In Vivo; 2023; 37(2):825-829. PubMed ID: 36881056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
    Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Yamada O; Hirakata H
    Ther Apher Dial; 2022 Apr; 26(2):345-356. PubMed ID: 34390314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study.
    Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Kidney Dis (Basel); 2021 Nov; 7(6):494-502. PubMed ID: 34901195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
    Fujikawa R; Nagao Y; Fujioka M; Akizawa T
    Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.
    Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Kidney Int Rep; 2021 Jul; 6(7):1840-1849. PubMed ID: 34307978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
    Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
    Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
    Pai S; Huang MQ; Maki K; Waldron M; Yoshikawa T; Keller T; Burnett J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1176():122754. PubMed ID: 34052557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
    Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enarodustat: First Approval.
    Markham A
    Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2021 May; 10(5):463-470. PubMed ID: 33788422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.